GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has submitted its financial results for the quarter and nine months ended December 31, 2025 to the stock exchanges. This is a routine compliance filing under SEBI's listing regulations, which require listed companies to share their quarterly results with the exchanges within the stipulated timeframe. The actual detailed numbers, including revenue, profit, and segment performance, would be available in the full results document. Investors will need to refer to the detailed financial statement to assess the company's performance during the quarter.
This is a procedural filing announcing the submission of results; it does not itself indicate any positive or negative change. Shareholders should look at the actual financial numbers in the results document to gauge business performance and any potential impact on the stock.